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An Australian estuarine isolate of Penicillium sp. MST-MF667 yielded
3 tetrapeptides named the bilaids with an unusual alternating LDLD
chirality. Given their resemblance to known short peptide opioid
agonists, we elucidated that they were weak (Ki low micromolar)
μ-opioid agonists, which led to the design of bilorphin, a potent and
selective μ-opioid receptor (MOPr) agonist (Ki 1.1 nM). In sharp con-
trast to all-natural product opioid peptides that efficaciously recruit
β-arrestin, bilorphin is G protein biased, weakly phosphorylating
the MOPr and marginally recruiting β-arrestin, with no receptor
internalization. Importantly, bilorphin exhibits a similar G protein
bias to oliceridine, a small nonpeptide with improved overdose
safety. Molecular dynamics simulations of bilorphin and the
strongly arrestin-biased endomorphin-2 with the MOPr indicate
distinct receptor interactions and receptor conformations that
could underlie their large differences in bias. Whereas bilorphin
is systemically inactive, a glycosylated analog, bilactorphin, is
orally active with similar in vivo potency to morphine. Bilorphin
is both a unique molecular tool that enhances understanding of
MOPr biased signaling and a promising lead in the development of
next generation analgesics.
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glycosylation
Developing ligands that target G protein-coupled receptors(GPCRs) in multiple functional states has attracted great
interest, particularly with increasing knowledge of GPCR struc-
ture (1–3). These novel ligands are expected to underpin the
development of agonists with superior pharmaceutically relevant
properties, including biased receptor signaling (4, 5), whereby
one downstream signaling pathway is favored over another. For
example, biased agonists that signal by differentially recruiting G
proteins over β-arrestin to the μ-opioid receptor (MOPr) could
deliver better analgesics, based on the view that down-regulating
β-arrestin recruitment diminishes adverse side effects (4, 6–8).
Exploiting this concept, the G protein-biased MOPr agonist
oliceridine (TRV130) is a potent analgesic in rodents, with lower
respiratory depression and gastrointestinal dysfunction compared
to morphine (7). Indeed, human clinical trials of oliceridine show
reduced respiratory impairment compared to morphine adminis-
tered at equi-analgesic doses (9). Reduced respiratory depression
delivers improved safety, potentially reducing the burden of opioid
overdoses, now at epidemic proportions in many jurisdictions (10).
Bioactive peptides display great promise for their novel phar-
macological properties (11). Since the discovery of the relatively
nonselective mammalian opioid peptides, the enkephalins, other
endogenous mammalian ligands, including the tetrapeptide
endomorphins that target the MOPr with high selectivity over
the related κ-opioid (KOPr) and δ-opioid (DOPr) subtypes, have
been found (12, 13). Natural peptide agonists containing a D-Ala
in the second position formed by a posttranslational modification
isolated from frog skin, dermorphin and deltorphin II, selectively
target MOPr and DOPr, respectively (14). Similar synthetic modi-
fications have yielded enhanced biological stability and receptor
selectivity. For example, introduction of D-Ala stabilizes the en-
kephalins to proteolysis, and further substitutions yield highly
stable, selective MOPr agonists such as DAMGO ([D-Ala2, N-
MePhe4, Gly5-ol]-enkephalin) (15). However, to our knowledge, all
endogenous opioid peptides acting on MOPr robustly recruit
arrestins and produce MOPr internalization (16–19). Here, we re-
port the discovery of 3 tetrapeptides, bilaids A–C (Fig. 1, [1a-3a]),
from an Australian estuarine isolate of Penicillium sp. MST-MF667
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[initially reported as P. bilaii (20); maximum likelihood tree pre-
sented in SI Appendix, Fig. S1]. Discovery of the bilaids, which re-
semble known opioid peptides but featuring an unusual alternating
sequence of antipodal amino acids (LDLD), led to our design of
bilorphin (3c), a MOPr agonist, with G protein signaling bias similar
to oliceridine. Bilorphin adopts a distinct conformational shape and
intermolecular interactions in molecular dynamics (MD) simula-
tions of the bilorphin–MOPr complex, consistent with predicted G
protein bias at related GPCRs. Together with its in vitro and in vivo
activity, we demonstrate that bilorphin provides a scaffold for the
development of stable, orally active opioid peptides that are biased
toward G protein signaling (3g).
Results
To date, the major opioid peptide families have only been de-
tected in vertebrates (21). Through a broader screening program,
we now report the discovery of 3 closely related tetrapeptides
(Fig. 1), bilaids A (1a, FvVf-OH), B (2a, FvVy-OH), and C (3a,
YvVf-OH), from the Australian estuarine-derived Penicillium sp.
MST-MF667. Solvent extracts of cultivations of MST-MF667
were subjected to solvent partition followed by reversed-phase
high-performance liquid chromatography (HPLC) to yield 1a
(0.15%), as well as traces of 2a (0.0018%) and 3a (0.0008%)
(Fig. 1). The chemical structures for 1a–3a, which resemble
opioid peptides albeit with a unique, alternating LDLD amino
acid configuration, were identified by spectroscopic analyses,
chemical derivatization and degradation, and Marfey’s analysis
and total synthesis. In addition to synthesizing 1a–3a, we pre-
pared and screened a series of related analogs for inhibition of
forskolin-induced cAMP formation in HEK cells expressing the
human MOPr (hMOPr) (SI Appendix, Table S1). Five hits de-
termined to be active at a concentration of 10 μM were tested for
competitive binding against the hMOPr agonist [3H]DAMGO.
Bilaid C (3a) bound with the highest affinity at the hMOPr (Ki =
210 nM, Fig. 2A and SI Appendix, Table S1), consistent with the
requirement for a Tyr moiety in the majority of peptide ligands
targeting opioid receptors (22). Bilaid A (1a) showed more
modest affinity (Ki = 3.1 μM) that was improved 4-fold through C-
terminal amidation (Ki = 0.75 μM, 1e), prompting us to apply this
modification to further analogs. Analogs of bilaid A having a
DLDL (1b, 1f), LLDD (1c, 1g), DDLL (1d), or LLLL (1h) con-
figuration were generally inactive, with the exception of FVVF-
NH2 (1h), which weakly inhibited cAMP formation at 10 μM.
These findings are consistent with previous SAR studies, which
revealed that having L-amino acids in position 2, other than those
that are Nα-alkylated (e.g., L-Pro), reduce opioid agonist activity
(23), as do D-amino acids in position 1 (24). Other bilaid analogs
showed no MOPr activity at 10 μM.
C-terminal amidation of bilaid C (Fig. 2A, 3b and SI Appendix,
Table S1) improved hMOPr affinity (Ki = 93 nM), consistent
with the increased binding of 1e over 1a. Dimethylation of the N-
terminal tyrosine residue (3c) resulted in significantly increased
potency (Ki = 1.1 nM), as has been observed for other opioid
peptides (25). This compound, which we name bilorphin, bound
with nearly 200-fold selectivity for hMOPr over hDOPr (Ki= 190 nM)
and 700-fold selectivity over hKOPr (Ki = 770 nM) (Fig. 2A
and SI Appendix, Table S1).
To assess functional activity of bilorphin, patch-clamp re-
cordings of G protein-activated, inwardly rectifying potassium
channel (GIRK) currents were made in rat locus coeruleus (LC)
neurons, which natively express MOPr but not DOPr or KOPr
(26). Bilorphin acted as an agonist with potency greater than
morphine. Its actions were completely reversed by the highly
MOPr selective antagonist CTAP (27) (n = 9, Fig. 2 B and C and
SI Appendix, Table S1), establishing that bilorphin does not act
on the closely related nociceptin or somatostatin (SST) receptors
expressed by LC neurons (28). The native peptide, bilaid C, was
14-fold weaker than morphine in the same assay system (29).
Bilaid C analogs with an acetylated N terminus (3d), or con-
taining all L-amino acids (3e and 3f), were inactive in LC neurons
at 10–30 μM, confirming the importance of a free N terminus
and the native LDLD motif for maintaining MOPr activity (SI
Appendix, Table S1).
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Fig. 1. Structures of bilaids, bilorphin, and bilactorphin.
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Fig. 2. (A) Competition for binding of [3H]DAMGO to hMOPr (human
recombinant MOPr) by the native bilaid YvVf-OH (3a), YvVf-NH2 (3b) and
bilorphin ([Dmt]vVf-NH2) (3c), as well as bilorphin to hDOPr ([
3H]DADLE
binding to human recombinant DOPr) and hKOPr ([3H] U69593 binding to
human recombinant KOPr). (B) Exemplar GIRK current recorded from a rat
LC neuron in response to Met-enk (Met-enk; 1 μM), bilorphin (1 μM) applied
for duration of bars shown, and its reversal by coapplication of the MOPr
selective antagonist, CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2, 1 μM).
(Scale bars, 50 pA, 5 min.) (C) Exemplar record of bilorphin, morphine, and
Met-enk–induced GGIRK in mMOPr-expressing AtT20 cells in response to SST
and opioids after alkylation of a fraction of receptors by the irreversible
MOPr antagonist β-chlornaltrexamine (β-CNA). (Scale bar, 0.2 nS, 1 min.) (D)
Agonist concentration–response relationships of opioids for activation of
GIRK current in LC neurons normalized to 1 μM Met-enk applied first as a
reference in each cell (n = 4–13 cells per data point; endo-2, endomorphin-2).
(E) Concentration–response curves of GGIRK induced by opioids in AtT20 cells
after reducing the receptor reserve.
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The relative potency and intrinsic efficacy of bilorphin in sig-
naling pathways was examined in AtT20 cells stably expressing
FLAG-tagged mouse MOPr (mMOPr) to enable bias analysis
(Fig. 2 C and E). To reliably determine the relative intrinsic
efficacy of bilorphin to activate G proteins (GGIRK), we partially,
irreversibly inactivated receptors to reduce the maximum response
to the high efficacy natural agonist, Methionine5-enkephalin
(Met-enk), to 80% of that produced by SST acting on native
SST receptors in the same cells (Fig. 2 C and E). Maximal acti-
vation of SST receptors normally produces a GGIRK increase
equivalent to a maximal activation of MOPr (30). Under these
conditions, bilorphin, morphine, and endomorphin-2 all displayed
similar maximal responses. All agonists displayed similar potencies
in the brain slice and cell assay, with the exception of Met-enk,
the reduced potency of which in brain slices is known to result
from its degradation by peptidases (31). As expected from brain
slice experiments, all 3 opioids were moderately efficacious but
less so than Met-enk (Fig. 2E and SI Appendix, Fig. S2A). In con-
trast, the G protein-biased, small molecule agonist oliceridine,
activated GGIRK significantly less efficaciously than either morphine
or bilorphin (Fig. 2E).
MOPr C-terminal phosphorylation, β-arrestin recruitment, and
internalization are thought to contribute to on-target opioid
analgesic side effects so that G protein-biased opioids that avoid
β-arrestin signaling should show an improved side effect profile
(4, 7, 8). We therefore assayed the activity of bilorphin for in-
ducing C-terminal phosphorylation, β-arrestin recruitment, and
MOPr internalization in the same AtT20 cell line. Agonist-
induced phosphorylation of residue serine 375 (Ser375) drives
β-arrestin recruitment and internalization (32). We determined
bilorphin-induced phosphoserine Ser375 (pSer375) phosphory-
lation using a phosphosite-specific antibody (Fig. 3 A and D)
(33). Surprisingly, and unlike other opioid peptides (19, 32, 33),
bilorphin produced low levels of pSer375 (30 μM, Fig. 3 A and D
and SI Appendix, Fig. S2B), which appeared less than that pro-
duced by morphine, but this difference was not statistically sig-
nificant (SI Appendix, Fig. S2B). Using MOPr-luciferase and
β-arrestin 2-YFP constructs, a bioluminescence resonance en-
ergy transfer (BRET) assay was performed to determine β-arrestin
2 recruitment (Fig. 3 B and D) (34). Similar to phosphorylation,
saturating concentrations of bilorphin induced very low levels of
BRET efficiency, significantly less than that produced by mor-
phine (30 μM, Fig. 3B). MOPr internalization was assessed im-
munocytochemically after 30 min of agonist treatment (Fig. 3 C
and D). Bilorphin produced almost no detectable internalization
of MOPr, compared to low levels induced by morphine and robust
internalization driven by both endomorphin-2 and Met-enk (Fig.
3D). In summary, when normalized to the maximum response to
Met-enk in each pathway, bilorphin displayed similar maximal G
protein efficacy to morphine with progressive reduction in relative
efficacy across pathways from Ser375 phosphorylation, β-arrestin
recruitment to internalization (Fig. 3D), suggesting that bilorphin
is a G protein-biased opioid.
Operational analysis, the de facto standard for quantifying bi-
ased signaling (35, 36), suggests that bilorphin is G protein biased
relative to morphine (SI Appendix, Fig. S2) but this requires
accurate determination of EC50, which was impractical for
bilorphin due to its very low internalization efficacy (SI Appendix,
Fig. S2) (35). Calculation of relative efficacy from maximum
response in each pathway provides a complementary estimate of
bias in signaling assays where all agonists are partial (36, 37).
This approach (SI Appendix, Fig. S2 and Table S2) substantiated
the G protein bias of bilorphin relative to morphine (19, 34). To
further substantiate the bias of bilorphin compared with mor-
phine and the established G protein biased agonist oliceridine,
both of which produce very little internalization, we enhanced
internalization by overexpressing GRK2-YFP and β-arrestin
2-HA (38). In GRK2-positive cells, morphine, oliceridine, and
bilorphin all produced clear internalization signals (SI Appendix,
Fig. S3A). Quantification shows that even under these amplified
conditions, bilorphin induces similar MOPr internalization to
oliceridine but significantly less than morphine at saturating
concentrations (SI Appendix, Fig. S3 B and C). Calculation of
bias relative to morphine with the ΔEMax method suggests that
bilorphin exhibits significant G protein bias that is similar to
oliceridine, further establishing it to be a G protein biased opioid
(SI Appendix, Fig. S3C).
The widely accepted mechanism for ligand bias is the stabili-
zation of distinct GPCR conformations that favor coupling to
different intracellular proteins (39). However, how such biased
agonists interact with the receptor binding pocket and the nature
of these biased receptor conformations, particularly for the
MOPr, is poorly understood. To this end, we performed mo-
lecular docking and MD simulations (40) to compare possible
biased receptor conformations of the G protein-biased bilorphin
versus β-arrestin–biased endomorphin-2. First, we analyzed the
predicted binding poses of bilorphin and endomorphin-2 after
1 μs of MD simulation to determine if interactions with the MOPr
binding pocket could differentiate these oppositely biased com-
pounds. The binding pose of bilorphin is shown in Fig. 4A and SI
Appendix, Fig. S4A and that of endomorphin-2 in Fig. 4B and SI
Appendix, Fig. S4B. There were similarities in how bilorphin and
endomorphin-2 interacted with the MOPr; both peptides bound
in the orthosteric pocket with the phenol groups of the Dmt
(bilorphin) or Tyr1 (endomorphin-2) orientated toward the in-
tracellular side of MOPr, and maintained interactions with
Asp1473.32, Trp2936.48, and His2976.52 (Fig. 4C). For the latter
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Fig. 3. (A) Representative images of S375 phosphorylation in AtT20 cells
induced by saturating concentrations (30 μM) of Met-enk, endomorphin-2,
morphine, and bilorphin after 5-min incubation. Colors enhanced uniformly
for all images for presentation purposes. (B) Time course of ligand-induced
BRET signal (ratio of emission of 535 nm/475 nm, baseline subtracted) in-
dicating β-arrestin 2 recruitment after incubation with saturating concen-
trations of agonists (shown by the arrow). The band represents the SE of
experiments repeated independently 6 times (each experiment in triplicate).
(C) Example images of MOPr internalization 30 min after incubation with
saturating concentrations of agonists. Dual staining was employed for
quantification (membrane receptor in green and internalized receptor in
red, colors enhanced uniformly for presentation purposes). (D) Maximal ef-
ficacy values of endomorphin-2, morphine and bilorphin relative to Met-enk
for GIRK channel activation, Ser375 phosphorylation, β-arrestin 2 re-
cruitment, and internalization (all normalized to Met-enk; nonnormalized
data in SI Appendix, Fig. S2).
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residue, bilorphin switched between a direct interaction and
hydrogen bonding via a bridging water molecule (Fig. 4 A, Inset).
However, there were also important differences in how these
peptides interact with the MOPr binding pocket. For bilorphin,
the rest of the tetrapeptide chain extended out toward the ex-
tracellular side of MOPr, making contacts with residues at the top
of TMs 1, 2, and 7, resulting in bilorphin, but not endomorphin-2,
interacting with Tyr751.39 in TM1. Conversely, endomorphin-2
extended toward ECL1 and ECL2 and the top of TM2.
Endomorphin-2 therefore interacted with the extracellular loops,
contacting W133ECL1 in ECL1 for the entire simulation time, and
transiently interacting with Cys217ECL2, Thr218ECL2, and Leu219ECL2
of ECL2. Whereas, these interactions were absent for bilorphin.
Moreover, endomorphin-2 made a greater number of contacts
with residues in TM3 and TM5 than bilorphin.
These predicted binding poses were validated by root mean
square deviation analysis showing stability of each ligand in the
binding pocket (SI Appendix, Fig. S4 C and D), and our docking
and MD protocol successfully recapitulated the binding pose of
DAMGO when compared to the cryo-electron microscopy
structure of the DAMGO-bound MOPr–Gi complex (SI Ap-
pendix, Fig. S5) (41).
Next, principal component analysis was employed to examine
the overall conformational changes in the receptor transmem-
brane helices in the presence of bilorphin or endomorphin-2.
The receptor conformations at each time point were projected
onto principal components (PC) 1 and 2 and plotted in Fig. 4D.
PC1 and PC2 accounted for 28.9% and 10.9% of the variance,
respectively. Both peptide–MOPr complexes sampled confor-
mations across PC2, but clustered differently based on PC1,
suggesting that the MOPr adopted distinct conformations when
bound to each biased agonist.
As depicted in SI Appendix, Fig. S4E, PC1 primarily described
alternative conformations in the extracellular region of the re-
ceptor close to the orthosteric binding site and, to a lesser extent,
differences in the intracellular portions of the helices. With
endomorphin-2 bound, there was an overall contraction of the
orthosteric site, due to inward movements of TMs 2, 3, 4, and 7.
Whereas, with bilorphin bound, there was a bulging of the
middle portion of TM1 and a shift outwards from the helix
bundle, relative to the endomorphin-2–bound receptor. These
alternative conformations of the helices were also reflected in
the volume of the orthosteric site, as with bilorphin bound the
binding pocket volume was on average 1.6 times greater than
with endomorphin-2 bound (42) (SI Appendix, Fig. S4F). On the
intracellular side of MOPr, PC1 described inward movements of
TMs 5, 6, and 7 with endomorphin-2 bound, compared to the
bilorphin-bound MOPr (SI Appendix, Fig. S4E). The result was a
more occluded intracellular cavity in the endomorphin-2–bound
MOPr, compared to that with bilorphin bound.
Analysis of the MD data therefore suggests that the different
ligand–residue interactions for these oppositely biased peptides
(with respect to the extracellular loops and TM1) may lead to the
alternative receptor conformations described by the principal
component analysis and, hence, the opposing bias profiles of
bilorphin and endomorphin-2.
We then evaluated bilorphin in vivo. Bilorphin failed to inhibit
nociception in the hotplate test in mice when administered
subcutaneously (s.c.) (100 mg/kg, n = 4) or intravenously (i.v.)
(50 mg/kg n = 4). By contrast, bilorphin was antinociceptive after
intrathecal injection (5 nmol per mouse, peak effect 41 ± 9%
MPE n = 4, versus 0 ± 1.5% for vehicle, n = 4), suggesting the
lack of systemic activity is due to poor penetration of the blood–
brain barrier (BBB). We therefore developed several bilorphin
analogs with substitutions thought to enhance BBB permeability,
including glycosylation near the C terminus (43). The di-
glycosylated analog, bilactorphin (3g), was a potent analgesic
after systemic administration (s.c; ED50 of 34 μmol/kg, 95%
confidence interval [CI] = 28–40 μmol/kg; SI Appendix, Fig. S6 A
and B), was nearly equipotent with morphine (ED50 of 27 μmol/kg,
95% CI = 24–30 μmol/kg SI Appendix, Fig. S6B) and was antag-
onized by coadministration of the opioid antagonist, naltrexone
(SI Appendix, Fig. S6A). Bilactorphin was also active after i.v.
(peak effect of 88.9 ± 11.8 versus 14.4 ± 1.8% MPE for vehicle,
n = 3–4) or oral administration (SI Appendix, Fig. S7). In contrast,
the monoglycosylated analog 3h was systemically inactive, consis-
tent with previous modified opioid peptides (43). These findings
establish that the natural LDLD opioid peptide backbone we have
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Fig. 4. Predicted binding poses of bilorphin (purple)
(A) and endomorphin-2 (orange) (B), and the posi-
tions of the surrounding binding pocket residues
(gray) obtained after molecular docking and 1 μs of
MD simulations. The salt bridge between the pro-
tonated amine of the ligands and Asp1473.32 is
marked as a dashed black line. TM7 has been re-
moved for clarity. (C) Ligand–residue interaction
fingerprints for the bilorphin–MOPr complex (pur-
ple) and endomorphin2–MOPr complex (orange).
Data are expressed as the percentage of simulation
time each residue is within 4.5 Å of the ligand, with
points radiating outwards from 0 to 100% in 20%
increments. (D) Principal component analysis was
performed on the alpha carbons of the receptor
transmembrane domains, before projecting the re-
ceptor conformations at each simulation time point
onto PC1 and PC2. The bilorphin–MOPr complex is in
purple, the endomorphin-2–MOPr complex in or-
ange, and the black point indicates the conformation
of the inactive MOPr model to which the peptides
were docked.
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discovered is a viable framework for development of G protein-
biased opioid analgesics. Like bilorphin, bilactorphin was a po-
tent partial opioid agonist of G proteins in AtT20 cells but
exhibited a small loss of potency compared with bilorphin (SI
Appendix, Fig. S6 C and D). Bilactorphin did, however, display
increased internalization and β-arrestin recruitment compared to
bilorphin (SI Appendix, Fig. S6 E and F) and thus might not be
suitable for directly testing the role of bias in opioid side-effect
profile. Alternative modifications that do not disrupt G protein
bias of the parent bilorphin might be better suited to enhance
BBB permeability.
Discussion
Nature has inspired many of the most well-known and widely
used analgesics, from natural salicin in willow (Salix) bark to
synthetic aspirin, from opioid poppy alkaloids such as morphine
and codeine to synthetic hydrocodone (Vicodin), oxycodone
(OxyContin), and buprenorphine (Subutex). Notwithstanding their
value in alleviating pain, serious adverse side effects, combined
with the challenge of addiction, abuse, and acquired tolerance,
render these analgesics (particularly opioids) far from ideal. There
is an urgent need to discover and develop new, safer and more
efficacious analgesics, with mechanisms of actions that mitigate
against risk.
We therefore investigated the analgesic potential of a class of
tetrapeptides, the bilaids (1a–3a), isolated from a Penicillium
fungus. Taking advantage of an unprecedented natural scaffold
comprising alternating LDLD configuration amino acids, which
imparts inherent biostability, we designed a peptide-based G
protein-biased MOPr agonist, bilorphin (3c). Furthermore, we
assembled proof-of-concept data that this pharmacophore can
be optimized to yield an orally active MOPr agonist analgesic,
bilactorphin (3g).
G protein-biased opioid agonists have been proposed as a
route to improving therapeutic profile (4, 7, 8). Among known
peptide opioid agonists, which typically are biased toward β-arrestin
signaling relative to morphine (19, 34), the pharmacological pro-
file of bilorphin is most unusual, although a synthetic opioid
cyclopeptide with G protein bias was recently reported (44).
Bilorphin enjoys an opioid signaling bias comparable to oliceridine,
a G protein-biased drug candidate in phase III clinical trials.
Glycosylation of bilorphin produced an analog active in vivo via
s.c. and oral administration, validating the bilorphin tetrapeptide
backbone as a platform for further development of druggable
signaling-biased opioid agonists. Preclinical development of other
G protein-biased agonists shows a favorable profile with reduced
respiratory depression and constipation. The first such compound
to reach clinical trials, oliceridine, was reported to have an in-
creased therapeutic window between antinociceptive and re-
spiratory depressive activity (7) and appears to be safer in humans
than morphine for equi-analgesic doses (9). Similarly, a series of
substituted fentanyl analogs was observed to produce an increased
therapeutic window for respiratory depression in mice, correlating
with increased G protein versus β-arrestin 2 recruitment (8).
To investigate whether bias could be explained by the differ-
ential interaction of bilorphin and endomorphin-2 with MOPr,
or by distinct receptor conformational changes initiated by each,
we undertook MD simulations with bilorphin and compared this
to the arrestin-biased opioid, endomorphin-2, bound to MOPr.
Both peptides were docked to the orthosteric binding site of
MOPr and displayed differences in ligand–residue interactions,
which may translate to their differing bias profiles. Notably,
endomorphin-2 transiently interacted with residues in ECL1 and
ECL2, including the conserved residue Leu219, proposed to
be important for arrestin-bias and ligand residence time at
the 5-HT2A and 5-HT2B receptors and other aminergic GPCRs
(45, 46). The cryo-electron microscopy–resolved structure of
the DAMGO–MOPr–Gi complex also showed DAMGO, which
robustly recruits arrestin, interacting with the receptor extracel-
lular loops (41). In contrast, bilorphin did not contact the extra-
cellular loops and instead interacted with TM1. Intriguingly, the
extracellular end of TM1 has also been identified as part of the
binding pocket for the G protein-biased GLP-1 agonist, ExP5 (47)
and, in addition, has been implicated in the allosteric communi-
cation between the binding site and intracellular domain for oli-
ceridine at the MOPr (48). Moreover, the interactions between
the peptides and the MOPr binding pocket appear to translate to
the divergent conformational changes observed by principal
component analysis, resulting in the MOPr adopting a distinct
conformation with bilorphin bound compared to endomorphin-2.
Specifically, with bound endomorphin-2, the extracellular portions
of the transmembrane domains moved inwards so that the
orthosteric binding pocket contracted relative to the bilorphin-
bound MOPr. On the intracellular side of the receptor TM5, 6,
and 7 adopted distinct positions depending on the bound peptide,
mainly an inward shift of these helices in the presence of
endormorphin-2, resulting in a more occluded intracellular cavity
for this arrestin-biased ligand. Of interest, this is in line with the
proposed binding pocket for arrestins at the base of the GPCR
being slightly smaller than those for G proteins (49, 50).
While it remains challenging at present to associate ligand-
induced GPCR conformations with differential coupling to G
proteins or arrestins, particularly in the absence of a large
structurally diverse panel of biased MOPr agonists, the subtle
differences in ligand–residue interactions and conformations of
the MOPr helices that we have modeled here may represent the
initial changes induced by the oppositely biased peptides, bilorphin
and endomorphin-2. These different interactions and MOPr
conformations may well lead to the different signaling profiles
reported for these biased peptide agonists at MOPr.
It remains uncertain, however, whether G protein bias per se is
the sole property contributing to the improved safety of new
opioid drugs such as oliceridine (9). Using receptor knockdown,
we have shown here that oliceridine has very low G protein ef-
ficacy compared with morphine, similar to findings using re-
ceptor depletion with a cAMP assay system (37). Similar low
efficacy results have recently been reported for another opioid,
PZM21, also claimed to be safer than morphine (4, 51).
Furthermore, it is difficult to evaluate maximal G protein effi-
cacy of novel biased agonists in other studies because assays were
insensitive to the relatively low G protein efficacy of morphine
(7, 8). Very low G protein efficacy may indeed be a confounding
factor in the preclinical and clinical studies of side effect profile,
given that other agonists with very low G protein efficacy such as
buprenorphine are not strongly G protein biased (19) but are
well characterized to produce less respiratory depression, and
overdose death than highly efficacious agonists such as morphine
and methadone (52). Because bilorphin is strongly G protein bi-
ased and has nearly equivalent maximal G protein efficacy to
morphine, further development of BBB penetrant analogs that
can release the parent molecule will facilitate direct test of the
influence of bias without being confounded by differing G protein
efficacy.
Finally, we have elucidated an analgesic pharmacophore based on
the discovery of the bilaids and related bilorphin and bilactorphin
motifs. Unusually, they derive from a microbial source, an untapped
resource for analgesics and worthy of further investigation. This
observation suggests that microbes may be an untapped resource for
new analgesics, deserving of further investigation.
Experimental Procedures. Full details on the materials and meth-
ods used are available in SI Appendix. Solvent extracts solid
phase cultivations of MST-MF667 were subjected to solvent
partition followed by reversed-phase HPLC, and chemical
structures were identified on the basis of detailed spectroscopic
analysis, chemical derivatization and degradation, Marfey’s
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analysis and total synthesis. All peptides were assembled man-
ually by stepwise solid-phase peptide synthesis. MOPr activity
was initially screened using competition opioid radioligand
binding to membranes from cultured cells expressing hMOPr,
hDOPr, or hKOPr receptors, then agonist activity screened at
hMOPr using inhibition of forskolin-stimmulated cAMP forma-
tion. Agonist activation of MOPr-coupled GIRK channels was
then quantified using superfusion onto LC neurons in rate brain
slices using whole-cell patch clamp recording. Signaling pathway
analysis was quantified in AtT20 cells stably expressing mMOPr
using perforated patch recording for GIRK channels activation
(G protein signal), fluorescence immunohistochemistry for Ser375
phosphorylation and MOPr internalization and arrestin recruit-
ment with a BRET-based approach. Molecular docking was
performed using the Bristol University Docking Engine (53). The
selected peptide–MOPr complexes were then embedded in a lipid
and cholesterol bilayer and used in all-atom MD simulations.
Multiple simulations (8 × 125 ns), with different initial velocities,
were performed under the Amber ff14SB and Lipid14 forcefields,
to yield a total of 1 μs of trajectory data for each peptide. Be-
havioral assays of analgesia were performed using the hotplate
latency assay in mice. Statistical analyses were performed as de-
scribed in SI Appendix. All values are expressed as means ± SEM,
except where noted otherwise (SI Appendix, Fig. S2).
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